Assessment of TK006 in Patients With Breast Cancer-related Bone Metastases
Phase 1 Trial of a Fully Human Monoclonal Antibody of Receptor Activator for Nuclear Factor-κ B Ligand (RNAKL, TK006) Safety, Pharmacokinetics, and Pharmacodynamics in Patients With Breast Cancer-related Bone Metastases
Sponsor: Jiangsu T-Mab Biopharma Co.,Ltd
Listed as NCT03239756, this PHASE1 trial focuses on Breast Cancer and remains ongoing. Sponsored by Jiangsu T-Mab Biopharma Co.,Ltd, it has been updated 6 times since 2017, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE1
-
Sep 2019 — Jan 2021 [monthly]
Unknown Status PHASE1
Status: Recruiting → Unknown Status
-
Jun 2018 — Sep 2019 [monthly]
Recruiting PHASE1
▶ Show 1 earlier version
-
Sep 2017 — Jun 2018 [monthly]
Recruiting PHASE1
First recorded
Jul 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Jiangsu T-Mab Biopharma Co.,Ltd
For direct contact, visit the study record on ClinicalTrials.gov .